Shares in Sun Pharma continued to fall for a second day in a row and was down 1.8 per cent at Rs 585. The stock had lost ground on Monday as well after the US Food and Drug Administration said that Sun Pharma was voluntarily recalling 2,528 bottles of its generic version of diabetes drug Glumetza from US-based Santarus Inc.

According to a Reuters report Sun began recalling the bottles of metformin HCL extended-release tables in the United States on January 28, 2014, after it received a customer complaint that one of the bottles contained tablets of epilepsy drug Gabapentin, the FDA said .

Shares in Sun Pharma have been among the top performers in the market over the last one year, after hopes of better performance led by growth in the US market.

GoodReturns.in